Cumberland Pharma (CPIX) Reports In-Line Q3 EPS of 6c; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts CPIX Hot Sheet
Join SI Premium – FREE
Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) reported Q3 EPS of $0.06, in-line with the analyst estimate of $0.06. Revenue for the quarter came in at $13.1 million versus the consensus estimate of $13.17 million.
Reaffirms guidance.
Reaffirms guidance.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- MarketWise Q2 billings rise 56% year-over-year to $91M
- Delta Air Lines Q2 earnings preview: softer profit expected amid fuel price headwinds
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
